Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
Weekly doses of semaglutide, a GLP-1 receptor originally developed to treat diabetes, could help approximately 93 million U.S. adults lose weight and reduce their risk of adverse cardiovascular events, according to new research published in Cardiovascular Drugs and Therapy. Novo Nordisk sells and markets subcutaneous treatments of semaglutide 2.4 mg under the brand name Wegovy.

New formula could mean diabetes and weight loss drugs such as semaglutide are only needed every 4 months

GLP-1 agonists are often taken as daily or weekly injections. A new delivery system could help make it so those same drugs are only required three times per year. 

November 28, 2023
Stop

Bayer ends blood thinner trial early due to lack of efficacy

The Independent Data Monitoring Committee recommended Bayer stop the trial due to the drug's poor performance compared to apixaban. 

November 22, 2023
Pills

ADHD medications associated with heightened CVD risk

"Although the effectiveness of ADHD medications has been demonstrated ... concerns remain regarding their potential cardiovascular safety," one research explained. 

November 22, 2023
A new gene-editing therapy has been tested on humans for the first time, resulting in a significant reduction in their low-density lipoprotein (LDL) cholesterol that could potentially last for decades. The study’s authors presented these early results at the AHA 2023 meeting.

Gene-editing therapy lowers cholesterol in high-risk heart patients—one dose could potentially last decades

While the therapy has been successfully tested on animals in the past, this study represents the first time it has been used on humans.

November 17, 2023
Cardiologist heart

A closer look at how weight loss drug semaglutide improves the cardiovascular health of obese patients without diabetes

Novo Nordisk shared initial results from the SELECT trial back in August, but now the full analysis—which includes data from more than 17,000 patients—has been published in The New England Journal of Medicine. 

November 14, 2023
Rasha Al-Lamee, MBBS, PhD, a cardiologist with the National Heart and Lung Institute in London, presented ORBITA, commented on the ORBITA-2 findings at the American Heart Association (AHA) 2023 meeting. #AHA #AHA23 #AHA2023

PCI benefits patients with stable chest pain, late-breaking data confirm

“Going forward, patients and medical teams have a choice of two pathways for chest pain relief: chest pain medication or PCI," one cardiologist said. 

November 13, 2023
tirzepatide injections Zepbound Eli Lilly. The U.S. Food and Drug Administration (FDA) cleared Eli Lilly and Company’s tirzepatide injections for chronic weight management in adult patients who are obese, overweight or present with at least one weight-related condition such as high blood pressure or high cholesterol. These weekly injections are being sold and distributed under the brand name Zepbound. Tirzepatide is also used in Mounjaro, FDA cleared in 2022 for improving glycemic control in adults.

FDA approves diabetes drug tirzepatide for chronic weight management under new name

The FDA issued its own statement about the approval, highlighting the importance of taking the drug in combination with an improved diet and regular physical activity.  

November 8, 2023
private equity corporatization business consolidation

Private equity-backed pharmaceutical company acquires stroke drug from Bayer

The drug, nimodipine, is a second-generation calcium channel blocker designed to prevent and treat cerebral vasospasm following an aneurysmal subarachnoid hemorrhage.

November 6, 2023
Displaying 33 - 40 of 231

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup